ClearBridge International Growth EAFE Strategy Q3 2025 Commentary

Market Overview - International equities showed mixed results in Q3 2025, with the MSCI EAFE Index rising 4.8%, driven by Asian markets and Canada, while Europe Ex U.K. underperformed [3] - The MSCI Emerging Markets Index advanced 10.6%, supported by a 20.7% rally in China, which constitutes 30% of that benchmark [3] - European markets experienced a slowdown in momentum due to inflation remaining above the European Central Bank's target, with a September reading of 2.2% [4] Economic Conditions - Japan's GDP grew modestly in Q2, aided by tourism, while manufacturing activity remained restrained [5] - The People's Bank of China cut key lending rates in July to address weaknesses in the real estate sector and sluggish consumer demand, with Q2 GDP growth at 5.2% year over year [5] Investment Strategy - The MSCI EAFE Value Index outperformed the MSCI EAFE Growth Index by over 500 basis points in Q3, with value stocks leading growth by more than 1,300 basis points year to date [6] - The ClearBridge International Growth Strategy maintained pace with its core MSCI EAFE benchmark, with sector positioning in IT and financials creating headwinds [12] Company Performance - London Stock Exchange faced a decline due to AI concerns impacting its desktop and data business, while Adyen's revenue missed expectations [13] - Banco Santander was acquired for its streamlined operations and cost-cutting measures, expected to improve profitability [14] - HSBC is well-positioned for growth in Asian wealth management, benefiting from inflows of mainland Chinese money [15] - KBC Group's strong capital position allows for capital distributions or acquisitions, with growing assets under management [16] Sector Contributions - Health care sector saw solid contributions, particularly from European biotechs Argenx and UCB, driven by strong sales and positive clinical trial results [20] - The strategy expanded into the Chinese biotechnology sector with the purchase of WuXi AppTec, known for efficient drug development [21] Portfolio Adjustments - The strategy added 10 positions while exiting 13, with significant purchases in financials and health care, including Prysmian, which is poised for growth in the power cables industry [22] - Softbank trades at a discount to its NAV, holding stakes in key technology companies [23] - Celestica is positioned for growth in AI infrastructure, with expected annual revenue growth of over 20% [24] Outlook - The regions of investment are making progress on growth and equity-friendly policies, with forecasts for double-digit EPS growth in the pan-European Stoxx 600 [27] - Emerging markets are outperforming developed markets, with a focus on China’s growth potential in AI and biotechnology [28][32]